Welcome to
Èçäàòåëüñòâî Àòìîñôåðà

· Æóðíàëû
· Êíèãè
· Î ïðîåêòå

·Ýëåêòðîííûå âåðñèè êíèã èçäàòåëüñòâà “Àòìîñôåðà” ïîñòóïèëè â ïðîäàæó

Èçäàòåëüñòâî “Àòìîñôåðà” èäåò â íîãó ñî âðåìåíåì è îòêðûâàåò íà ñâîåì ñàéòå ðàçäåë ýëåêòðîííûõ âåðñèé ñâîèõ êíèã. Òåïåðü âû ìîæåòå ïðèîáðåñòè íå òîëüêî òðàäèöèîííóþ áóìàæíóþ êíèãó â êàðòîííîì ïåðåïëåòå, íî è .pdf-ôàéë, ñíàáæåííûé ãèïåðññûëêàìè íà êàæäóþ ãëàâó èçäàíèÿ.  ýëåêòðîííîé âåðñèè ïðîùå îòûñêàòü ðèñóíîê è òàáëèöó. ×òîáû îáðàòèòüñÿ ê íèì, äîñòàòî÷íî íàæàòü íà ññûëêó íà êàæäûé èç íèõ. Èñ÷åçëà çàâèñèìîñòü îò òèðàæà – âû ìîæåòå ïðèîáðåñòè äàæå òå áåñòñåëëåðû, òèðàæ êîòîðûõ óæå ðàçîøåëñÿ, òàêèå êàê “Ñàðêîèäîç” èëè “Çàáîëåâàíèÿ îðãàíîâ äûõàíèÿ ïðè áåðåìåííîñòè”. Óïðîñòèëîñü ïîëó÷åíèå âàìè êíèã – â òå÷åíèå äâóõ ðàáî÷èõ äíåé ïîñëå îïëàòû òðåáóåìûå ôàéëû ïðèäóò íà âàø e-mail. Íó è íàêîíåö, öåíà – ýëåêòðîííûå âåðñèè íàøèõ êíèã ãîðàçäî äåøåâëå, ÷åì áóìàæíûå èçäàíèÿ. Çàêàçûâàéòå ýëåêòðîííûå âåðñèè êíèã èçäàòåëüñòâà “Àòìîñôåðà” íà ñàéòå, à òàêæå ïî òåëåôîíó: (495) 730-63-51 è ïî e-mail: atm-press2012@yandex.ru



ÈÍÒÅÐÍÅÒ-ÌÀÃÀÇÈÍ
Èçäàòåëüñòâî Àòìîñôåðà


Òåëåôîí èçäàòåëüñòâà

  
Ëå÷åáíîå äåëî
2013 / N 1

Äèàáåòè÷åñêàÿ êàðäèàëüíàÿ àâòîíîìíàÿ íåâðîïàòèÿ (ñïèñîê ëèòåðàòóðû)
È.À. Ñòðîêîâ, À.Â. Çèëîâ, À.À. Ôîêèíà, Æ.Ñ. Àëüáåêîâà, Â.À. Ãîëîâà÷åâà

Ñïèñîê ëèòåðàòóðû 1. Rundles R.W. Diabetic neuropathy. General review with report of 125 cases // Medicine – 1945 – Vol.24 – P.111–160. 2. Low P.A., Zimmerman B.R., Dyck P.J. Comparison of distal sympathetic with vagal function in diabetic neuropathy // Muscle Nerve – 1989 – Vol.9 – P.592–596. 3. Low P.A., Sandroni P., Fealey R.D. et al. Detection of small-fiber neuropathy by sudomotor testing // Muscle Nerve –2006 – Vol.34 – P.57–61. 4. Smith A.G., Russell J., Feldman E.L. et al. Lifestyle intervention for pre-diabetic neuropathy // Diabetes care – 2006 – Vol.29 – P.1294–1299. 5. Low P.A., Benrud-Larson L.M., Sletten D.M. et al. Autonomic symptoms and diabetic neuropathy: a population-based study // Diabetes Care – 2004 – Vol.27 – P.2942–2947. 6. Neil H.A., Thompson A.V., John S. et al. Diabetic autonomic neuropathy: the prevalence of impaired heart rate variability in a geographically defined population // Diabet Med – 1989 – Vol.6 – P.20–24. 7. Low P.A., Benrud-Larson L.M., Sletten D.M. et al. Autonomic symptoms and diabetic neuropathy: a population-based study // Diabetes Care – 2004 – Vol.27 – P.2942–2947. 8. Tesfaye S., Boulton A.J.M., Dyck P.J. et al. Diabetic Neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatment // Diabetes Care – 2010 – Vol.33 – P.2285–2293. 9. Vinic A., Ziegler D. Diabetic cardiovascular autonomic neuropathy // Circulation – 2007 – Vol.115 – P.387–397. 10. Ewing D.J., Campbell I.W., Murray A. et al. Immediate heart rate response to standing: simple test of autonomic neuropathy in diabetes // Br Med J – 1978 – Vol.1 – P.145–147. 11. Ewing D.J., Campbell I.W., Clarke B.F. The natural history of diabetic autonomic neuropathy // Q J Med – 1980 – Vol.49 – P.95–108. 12. Ewing D.J., Boland O., Neilson J.M. et al. Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients // Diabetologia – 1991 – Vol.34 – P.182–185. 13. Maser R.E., Mitchell B.D., Vinic A.I. et al. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis // Diabetes Care – 2003 – Vol.26 – P.1895–1901. 14. Dyck P.J., Kratz Ê.Ì., Karnes J.L. et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort. The Rochester Diabetic Neuropathy Study Neurology 1993; 43:817–30. 15. Dyck P.J., Litchy W.J., Lehman K.F. et al. Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects. // Neurology. – 1995. – Vol. 45. - ¹6. – Ð.1115–1121. 16. Brownlee M. Biochemistry and molecular cell biology of diabetic complication // Nature, 2001; 414: 813–820. 17. Boulton A. J.M., Malik R. A., Arezzo J. C., Sosenco J. M. Diabetic Somatic Neuropathies. // Diabetes Care – 2004 - Vol.27 – P.1458–1486. 18. Vinik A.I., Erbas T. Recognizing and treating diabetic autonomic neuropathy. // Clev Clin J Med – 2001 – Vol.68 – P. 928–944. 19. The DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy // Ann Intern Med – 1995 – Vol.122 – P.561–568. 20. The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus // N Engl J Med –1993 – Vol.329 – P.977–986. 21. Albers J.W., Herman W.H., Pop-Busui R. et al. Effect of prior intensive insulin treatment during the DCCT on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010; 33:1090–1096. 22. Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. // Diabetes, 2005; 54: 1615–1625. 23. Dyck P.J., Thomas P.K. Diabetic neuropathy, 2nd ed., Philadelphia: W.B. Saunders – 1999. – P. 481–503. 24. Ziegler D., H.-J. Tritschler, Ñòðîêîâ È.À., Àìåòîâ À.Ñ. Ëå÷åíèå äèàáåòè÷åñêîé ïîëèíåâðîïàòèè òèîêòîâîé êèñëîòîé (îáçîð ëèòåðàòóðû) // Ôàðìàòåêà – 2008 - ¹17 – ñòð.28–35. 25. Ziegler D., Reljanovic M., Mehnert H. et al. α-Lipoic acid in the treatment of diabetic polyneuropathy in Germany: Current evidence from clinical trials // Exp.Clin. Endocrinol Diabetes - 1999 - Vol. 107 - P. 421–430. 26. Bachmann W., Forster H., Mehnert H. Experimental studies in animals on the effect of a protein-free blood extract on the metabolism of glucose // Arzneimittel-Forschung/Drug Research – 1968- Vol.18 – P.1023–1027. 27. Reichel H., Weiss C., Leichtweiss H.P. The effects of a blood extract on the oxygen uptake of isolated artificially perfused kidneys and skeletal muscles in rats // Arzneimittel-Forschung/Drug Research – 1965 – Vol.15 (7) – P.756–757. 28. Jensen W., Beck E. Treatment of the diabetic polyneuropathy. A controlled double blind study //Med Welt–1987–Vol.38–P.836–841. 29. Ñòðîêîâ È.À., Ìîðãîåâà Ô.Ý., Ñòðîêîâ Ê.È. Òåðàïåâòè÷åñêàÿ êîððåêöèÿ äèàáåòè÷åñêîé ïîëèíåâðîïàòèè è ýíöåôàëîïàòèè àêòîâåãèíîì // Ðóññê ìåäèö æóðí – 2006 - ¹9 – ñòð.698–703. 30. Ziegler D., Movsesyan L., Mankovsky B. et al. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients // Diabetes Care – 2009 – Vol.32 (8) – P.1479–1484. 31. Buchmayer F., Pleiner J., Elmlinger M.W. et al. Actovegin®: A biological drug for more than 5 decades // Wiener Medizinische Wochenschrift – 2011 – Vol.161 – P.80–88.
  

[ Ñîäåðæàíèå âûïóñêà N 1 | Âûïóñêè æóðíàëà | Ñïèñîê æóðíàëîâ ]